The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

Neurofluids is a term introduced to define all fluids in the brain and spine such as blood,
cerebrospinal fluid, and interstitial fluid. Neuroscientists in the past millennium have steadily …

The formation of toxic Amyloid β-peptide (Aβ) oligomers is one of the earliest events in the
molecular pathology of Alzheimer's Disease (AD). These oligomers lead to a variety of …

Amyloid-β peptide (Aβ) forms metastable oligomers> 50 kDa, termed AβOs, that are more
effective than Aβ amyloid fibrils at triggering Alzheimer's disease-related processes such as …

Alzheimer's disease (AD) is a chronic neurodegenerative disorder associated with
dementia. To overcome the limitations of diagnosis and treatment nanotechnology research …

The amyloid cascade hypothesis for Alzheimer's disease is still alive, although heavily
challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis' claim that …

The interplay between viral infection and Alzheimer's disease (AD) has long been an area of
interest, but proving causality has been elusive. Several recent studies have renewed the …

Significant data suggest that soluble Aβ oligomers play an important role in Alzheimer's
disease (AD), but there is great confusion over what exactly constitutes an Aβ oligomer and …

Most neurodegenerative diseases are characterized by the accumulation of protein
aggregates, some of which are toxic to cells. Mounting evidence demonstrates that in …

Alzheimer's disease (AD) is a major adult-onset neurodegenerative condition with no
available treatment. Compelling reports point amyloid-β (Aβ) as the main etiologic agent that …